Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland.
Neuro Center, Neurology, Kuopio University Hospital, Kuopio, Finland.
J Alzheimers Dis. 2018;62(2):789-794. doi: 10.3233/JAD-170854.
Several studies have reported reduced risk of cancer in patients with Alzheimer's disease (AD) or Parkinson's disease. The relationship between cancer and frontotemporal lobar degeneration (FTLD) has not been previously reported. Here, our aim was to evaluate the occurrence of cancer in Finnish FTLD patients with a high proportion of C9ORF72 repeat expansion carriers in comparison to age- and sex-matched group of AD patients and control subjects classified as not cognitively impaired (NCI). The prevalence of cancer was 9.7% in FTLD, 18.7% in AD, and 17.4% in NCI (FTLD versus AD p = 0.012, FTLD versus NCI p = 0.029) groups. No differences were observed between C9ORF72 repeat expansion carriers and non-carriers inside the FTLD group. To our knowledge, this is the first study showing significantly lower prevalence of cancer in FTLD patients compared to patients with AD or NCI subjects. Our data suggest an inverse association between neurodegeneration and cancer and that FTLD-specific mechanisms may underlie the especially strong inverse association observed in this study.
几项研究报告称,阿尔茨海默病(AD)或帕金森病患者的癌症风险降低。癌症与额颞叶变性(FTLD)之间的关系以前尚未报道过。在这里,我们的目的是评估在芬兰 FTLD 患者中,与年龄和性别匹配的 AD 患者以及被归类为无认知障碍(NCI)的对照组相比,癌症的发生情况,FTLD 患者中有很高比例的 C9ORF72 重复扩展携带者。FTLD、AD 和 NCI 组的癌症患病率分别为 9.7%、18.7%和 17.4%(FTLD 与 AD 相比 p=0.012,FTLD 与 NCI 相比 p=0.029)。FTLD 组中,C9ORF72 重复扩展携带者和非携带者之间未观察到差异。据我们所知,这是第一项表明 FTLD 患者的癌症患病率明显低于 AD 患者或 NCI 患者的研究。我们的数据表明神经退行性变与癌症之间存在反比关系,并且 FTLD 特异性机制可能是本研究中观察到的特别强的反比关系的基础。